(Q51202982)

1 April 2018

title

Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications. (English)

1 reference

1 April 2018

author

Emanuel Raschi

5

1 reference

1 April 2018

Lars L. Gustafsson

8

1 reference

1 April 2018

author name string

M Bennie

1

1 reference

1 April 2018

I Bishop

2

1 reference

1 April 2018

B Godman

3

1 reference

1 April 2018

C Barbui

4

1 reference

1 April 2018

S Campbell

6

1 reference

1 April 2018

J Miranda

7

1 reference

1 April 2018

publication date

1 February 2013

1 reference

1 April 2018

International Journal of Clinical Practice

published in

1 reference

1 April 2018

volume

67

1 reference

1 April 2018

page(s)

170-180

1 reference

1 April 2018

issue

2

1 reference

1 April 2018

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

cites work

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Ongoing pharmaceutical reforms in France: implications for key stakeholder groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Policies to enhance prescribing efficiency in europe: findings and future implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Potential savings without compromising the quality of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Generic olanzapine: health authority opportunity or nightmare?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Economic issues in access to medications: schizophrenia treatment in England.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Prevalence, incidence and persistence of antipsychotic drug prescribing in the Italian general population: retrospective database analysis, 1999-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Use of antipsychotic medications in Australia between July 1995 and December 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Increasing off-label use of antipsychotic medications in the United States, 1995-2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

The spurious advance of antipsychotic drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Modern antipsychotic drugs: a critical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Impact of regulatory changes on first- and second-generation antipsychotic drug consumption and expenditure in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Adverse effects of atypical antipsychotics : differential risk and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Atypical antipsychotic drugs and the risk of sudden cardiac death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Risperidone versus other atypical antipsychotics for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Clinical equivalence of generic clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Generic clozapine: outcomes after switching formulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Switching from brand-name to generic psychotropic medications: a literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

A cluster randomized controlled trial aimed at implementation of local quality improvement collaboratives to improve prescribing and test ordering performance of general practitioners: study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Block design allowed for control of the Hawthorne effect in a randomized controlled trial of test ordering

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Evidence-based pharmacotherapy of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Clozapine safety, 35 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Coping with changes in the Defined Daily Dose in a longitudinal drug consumption database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Interpreting the results of observational research: chance is not such a fine thing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Pharmaceutical policies in European countries in response to the global financial crisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

Enhancing the rational use of new medicines across European health care systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

The ‘Wise List’- A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

The Role of the Family and Improvement in Treatment Maintenance, Adherence, and Outcome for Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12100

21 January 2018

Identifiers

DOI

10.1111/IJCP.12100

1 reference

1 April 2018

PubMed ID

23305478

1 reference

1 April 2018